Introduction
============

Congenital hyperthyroidism caused by activating mutations of the thyrotropin receptor (*TSHR*) gene is a rare disorder. Most cases of congenital hyperthyroidism are autoimmune forms caused by maternal thyroid stimulating immunoglobulins. Autoimmune congenital hyperthyroidism shows a transient course, lasting approximately 4 months after birth, and resolving when maternal antibodies are eliminated from the blood of the infant. However, nonautoimmune congenital hyperthyroidism by activating germline mutations in the *TSHR* gene shows a persistent and severe hyperthyroidism. Clinical manifestations of nonautoimmune congenital hyperthyroidism might occur from the fetus and cause tachycardia, arrhythmia, intrauterine growth retardation and premature birth. There are 2 types of activating *TSHR* germline mutations. One is familial nonautoimmune hyperthyroidism (FNAH), an autosomal dominant disorder, and the other is sporadic nonautoimmune hyperthyroidism (SNAH), caused by *de novo* mutations \[[@b1-apem-2018-23-4-235]\]. Compared to FNAH, SNAH tends to occur at a younger age, present more severe clinical symptoms. These findings might be influenced by genetic, epigenetic or environmental factors including in vitro activity of *TSHR* mutations \[[@b2-apem-2018-23-4-235]\]. To date, a total of 17 patients with SNAH by 12 activating mutations of the *TSHR* gene have been reported in the literature \[[@b2-apem-2018-23-4-235]-[@b4-apem-2018-23-4-235]\]. Herein, we report a case of sporadic nonautoimmune congenital hyperthyroidism by a missense mutation of the *TSHR* gene for the first time in South Korea.

Case report
===========

A woman gave birth to a boy during an emergency cesarean section at 33 weeks of gestation due to fetal tachycardia. The birth weight was 2,280 g (50th--75th percentile), height was 43 cm (10th--25th percentile), and head circumference was 31 cm (50th--75th percentile). After birth, the boy was treated with meconium aspiration syndrome in neonatal intensive care unit. Approximately 4 days later, the patient recovered with mechanical ventilation, but continued to have tachycardia. Electrocardiography and echocardiography was normal except sinus tachycardia. Thyroid function test showed hyperthyroidism with increased free thyroxine (fT~4~, 3.98 ng/dL; normal reference value, 0.85--1.86 ng/dL), total triiodothyronine (T~3~, 10.52 ng/mL; normal reference value, 0.78--1.82 ng/mL) and decreased thyroid-stimulating hormone (TSH, 0.05 mIU/L; normal reference value, 0.17--4.05 mIU/L). Test for antibodies to *TSHR*, thyroid peroxidase, and thyroglobulin were negative. A thyroid ultrasound revealed increased vascularity and a diffuse goiter. The patient\'s mother had no history of any thyroid disease.

The patient was treated with propylthiouracil (PTU, 5 mg/kg) and propranolol for short-term management of thyroid storm \[[@b5-apem-2018-23-4-235]\], but showed persistent hyperthyroidism even after 1 month of treatment. One more month of intensive treatment with an increased dose of PTU (7.5 mg/kg) could only lead to subclinical hyperthyroidism (fT~4~, 1.07 ng/dL; T~3~, 2.54 ng/mL; TSH, 0.01 mIU/L). At 3 months after birth, a forehead protrusion was observed and the anterior fontanelle could not be palpated on physical examination. Brain computed tomography revealed hydrocephalus due to craniosynostosis and the patient underwent surgery to place a ventriculoperitoneal shunt. After 6 more months of treatment, thyroid function tests recovered to normal and tachycardia improved. PTU treatment was replaced with methimazole and euthyroid state was maintained for 2 months. When the dose of methimazole was reduced (0.3 mg/kg), a relapse of hyperthyroidism occurred. At 12 months of age (corrected age of 10 months), the patient's height and weight were in the 50th--75th and 25th--50th percentile, respectively, in addition to exhibiting delayed milestones (cognitive skills at 7 months, receptive communication at 5 months, expressive communication at 6 months, fine motor at 6 months, and gross motor at 7 months). Moreover, the patient's bone age was estimated to be 2 years and 8 months, which was markedly advanced compared to his chronological age.

Molecular genetic analysis was performed by direct sequencing of *TSHR*. Genomic DNA was isolated from peripheral blood leukocytes using a QIAmp DNA Mini Kit (Qiagen, Hilden, Germany). Polymerase chain reaction (PCR) was performed using gene-specific primers for all coding exons and splice junctions of *TSHR* as previously described \[[@b6-apem-2018-23-4-235]\]. PCR amplicons were bi-directionally sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). DNA chromatograms were analyzed using Sequencher software version 5.0 (Gene Codes, Ann Arbor, MI, USA) and the mutation was described according to the Human Genome Variation Society nomenclature. RefSeq ID: NM_000369.2 was used for reference sequences. Direct sequencing of the PCR products revealed the heterozygous missense mutation of c.1899C\>A (p.Asp633Glu) in exon 10 of *TSHR*. No mutation was observed in all parents in a familial genetic study ([Fig. 1](#f1-apem-2018-23-4-235){ref-type="fig"}). Therefore, c.1899C\>A (p.Asp633Glu) was deemed a *de novo* mutation. The variant was neither found in ExAC nor 1000 genomes. In *In silico* analysis, the variant was predicted deleterious by SIFT (<http://provean.jcvi.org/protein_batch_submit.php>), probably damaging by Polyphen-2 (<http://genetics.bwh.harvard.edu/pph2/>) and disease causing by Mutation Taster (<http://www.mutationtaster.org/>). The patient continues to be treated with antithyroid medication and maintains a euthyroid state.

This report was approved by the Institutional Review Board (IRB) at the Catholic University of Korea, Seoul St. Mary's Hospital. Informed consent was waived by the IRB.

Discussion
==========

In 1995, SNAH was first reported by Kopp et al. \[[@b1-apem-2018-23-4-235]\], who characterized it as severe thyrotoxicosis during the neonatal period or infancy. [Table 1](#t1-apem-2018-23-4-235){ref-type="table"} summarizes the clinical features of 17 patients with sporadic non-autoimmune congenital hyperthyroidism by 12 activating mutations of the *TSHR* gene. Most of the SNAH patients who have been reported to date have exhibited manifestations of hyperthyroidism during the newborn period \[[@b1-apem-2018-23-4-235],[@b4-apem-2018-23-4-235],[@b6-apem-2018-23-4-235]-[@b15-apem-2018-23-4-235]\]. Many of the reported SNAH patients were born prematurely or with a low birth weight \[[@b1-apem-2018-23-4-235],[@b6-apem-2018-23-4-235],[@b8-apem-2018-23-4-235]-[@b13-apem-2018-23-4-235]\]. In particular, the patient reported by Holzapfel et al. \[[@b16-apem-2018-23-4-235]\] presented with thyrotoxicosis during the fetal period. The patient in the present study was born prematurely as well and presented with tachycardia during the fetal period. In addition, the patient had thyroid hypertrophy, craniosynostosis with advanced bone age, poor weight gain, and mild developmental delay. These clinical features are similar to other SNAH patients. Specifically, craniosynostosis was reported in 7 patients, while advanced bone age was confirmed in 12 patients. Moreover, there have been five SNAH patients without goiter and proptosis was documented in 7 of the 17 patients. Additional symptoms that have been reported for SNAH patients include jaundice, diarrhea, apnea, asphyxia, and hepatosplenomegaly. To date, a total of 12 *TSHR* gene mutations in less than 20 cases have been reported; however, there is no definite genotype-phenotype relationship ([Table 1](#t1-apem-2018-23-4-235){ref-type="table"}).

Somatic mutations of *TSHR* residue 633 (p.Asp633Glu, p.Asp633Tyr, p.Asp633His, and p.Asp633Ala) have been reported for an autonomously functioning thyroid nodule as well as toxic thyroid adenoma tissue of patients with hyperthyroidism. The same amino acid residue was also reported to be altered in a previous case of nonautoimmune congenital hyperthyroidism, consisting of an aspartate to tyrosine substitution \[[@b9-apem-2018-23-4-235]\]. However, because of the different base substitution, the patient in this report has a novel missense variant. In addition, this is the first report of SNAH in South Korea. For treatment of nonautoimmune congenital hyperthyroidism, antithyroid drugs, such as PTU or methimazole, are used. However, several reported cases were not adequately treated with medication alone, eventually requiring ablative treatment such as radioiodine therapy or thyroidectomy \[[@b1-apem-2018-23-4-235],[@b9-apem-2018-23-4-235],[@b10-apem-2018-23-4-235],[@b12-apem-2018-23-4-235],[@b14-apem-2018-23-4-235]\]. At present, the patient in this report is being treated with antithyroid medication alone. If diagnosis and treatment are delayed, nonautoimmune congenital hyperthyroidism may cause irreversible complications such as mental retardation. Therefore, early diagnosis and prompt treatment with genetic counseling are necessary.

In conclusion, we identified a new case of SNAH caused by an activating mutation of the *TSHR* gene in a premature newborn with persistent tachycardia after birth. To date, a total of 12 activating mutations of the *TSHR* gene in less than 20 cases have been reported. Unlike autoimmune congenital hyperthyroidism, SNAH shows a persistent and severe hyperthyroidism. Furthermore, thyroidectomy and radioactive iodine therapy are inevitable to prevent long-term complications. The diagnosis is challenging due to lack of genotype-phenotype correlation, thus early genetic screening is a key to minimizing permanent sequelae.
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###### 

Clinical features of 17 patients with sporadic nonautoimmune congenital hyperthyroidism by 12 activating mutation of the *TSHR* gene

  Case                               Onset of hyperthyroidism   Gestational age/birth weight   Clinical manifestation related to hyperthyroidism                                                                      Mutation        Treatment                Reference
  ---------------------------------- -------------------------- ------------------------------ ---------------------------------------------------------------------------------------------------------------------- --------------- ------------------------ -------------------------------------------------
  1                                  Fetal period               38 wk/2,410 g                  Fetal tachycardia, advanced bone age, poor weight gain                                                                 p.Ser281Asn     Antithyroid drugs        Scaglia et al. \[[@b17-apem-2018-23-4-235]\]
  Total thyroidectomy                                                                                                                                                                                                                                          
  2                                  Fetal period               38 wk/2,600 g                  Goiter, craniosynostosis, proptosis, advanced bone age, growth retardation, mental retardation                         p.Ser505Asn     Antithyroid drugs        Holzapfel et al. \[[@b16-apem-2018-23-4-235]\]
  Subtotal thyroidectomy                                                                                                                                                                                                                                       
  3                                  Newborn period             39 wk/3,500 g                  Poor weight gain, diarrhea, excessive sweating and irritability                                                        p.Ala623Val     Antithyroid drugs        Aycan et al. \[[@b4-apem-2018-23-4-235]\]
  4                                  Newborn period             32 wk/1,660 g                  Goiter, hyperactivity, mental retardation, advanced bone age                                                           p.Phe631Leu     Antithyroid drugs        Kopp et al. \[[@b1-apem-2018-23-4-235]\]
  Subtotal thyroidectomy                                                                                                                                                                                                                                       
  Radioiodine treatment                                                                                                                                                                                                                                        
  5                                  Newborn period             36 wk/2,520 g                  Craniosynostosis                                                                                                       p.Ser281Asn     Antithyroid drugs        Grüters et al. \[[@b14-apem-2018-23-4-235]\]
  Total thyroidectomy                                                                                                                                                                                                                                          
  6                                  Newborn period             34 wk/3,290 g                  Tachycardia, tachypnea, craniosynostosis, dolichocephaly, advanced bone age, midface hypoplasia, proptosis             p.Ser281Asn     Antithyroid drugs        Chester et al. \[[@b13-apem-2018-23-4-235]\]
  7                                  Newborn period             32 wk/1,690 g                  Goiter, proptosis, advanced bone age, hepatosplenomegaly, jaundice                                                     p.Met453Thr     Antithyroid drugs        de Roux et al. \[[@b18-apem-2018-23-4-235]\]
  8                                  Newborn period             36 wk/3,040 g                  Goiter, proptosis, advanced bone age, delayed pubertal and psychomotor development, mental retardation, splenomegaly   p.Met453Thr     Subtotal thyroidectomy   Lavard et al. \[[@b12-apem-2018-23-4-235]\]
  Radioiodine treatment                                                                                                                                                                                                                                        
  9                                  Newborn period             38 wk/2,600 g                  Goiter, craniosynostosis, proptosis                                                                                    p.Ser505Asn     Antithyroid drugs        Schwab et al. \[[@b15-apem-2018-23-4-235]\]
  Total thyroidectomy                                                                                                                                                                                                                                          
  10                                 Newborn period             37 wk/2,250 g                  Goiter                                                                                                                 p\. Ala428Val   Antithyroid drugs        Börgel et al. \[[@b7-apem-2018-23-4-235]\]
  11                                 Newborn period             32 weeks/1,860 g               Goiter, craniosynostosis, advanced bone age                                                                            p.Leu512Gln     Antithyroid drugs        Nishihara et al. \[[@b8-apem-2018-23-4-235]\]
  Radioiodine treatment                                                                                                                                                                                                                                        
  12                                 Newborn period             35 wk/2,050 g                  Goiter, advanced bone age, accelerated statural growth, speech disturbance, mental retardation, eyelid retraction      p.Ile568Thr     Antithyroid drugs        Tonacchera et al. \[[@b11-apem-2018-23-4-235]\]
  13                                 Newborn period             33 wk/1,450 g                  Goiter, mental retardation, craniosynostosis, mild proptosis                                                           p.Thr632Ile     Antithyroid drugs        Kopp et al. \[[@b10-apem-2018-23-4-235]\]
  Subtotal thyroidectomy                                                                                                                                                                                                                                       
  Radioiodine treatment                                                                                                                                                                                                                                        
  14                                 Newborn period             36 wk/2,040 g                  Goiter, craniosynostosis, dolichocephaly, proptosis, hepatomegaly, periorbital edema, advanced bone age                p.Asp633Tyr     Antithyroid drugs        Bircan et al. \[[@b9-apem-2018-23-4-235]\]
  Subtotal thyroidectomy (3 times)                                                                                                                                                                                                                             
  15                                 Infancy                    37 wk/2,500 g                  Goiter, advanced bone age                                                                                              p.Val597Met     Antithyroid drugs        Esapa et al. \[[@b19-apem-2018-23-4-235]\]
  Total thyroidectomy                                                                                                                                                                                                                                          
  16                                 Infancy                    40 wk/2,540 g                  Goiter, advanced bone age, atopic dermatitis, growth retardation                                                       p.Ser505Asn     Antithyroid drugs        Fuhrer et al. \[[@b20-apem-2018-23-4-235]\]
  17                                 14 Months                  40 wk/4,000 g                  Diarrhea, increased growth velocity, advanced bone age                                                                 p.Pro639Ser     Antithyroid drugs        Agretti et al. \[[@b3-apem-2018-23-4-235]\]
